Acoramidis ATTR Cm denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for acoramidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits the Quantity of Acoramidis for ATTR-CM — and How to Appeal

A quantity-limit denial for acoramidis means Aetna's policy caps the amount that can be dispensed per fill or per period, and the prescription as written exceeds that cap. For a chronic disease like ATTR-CM — where treatment is ongoing and the prescribed regimen is set by the FDA-approved label — quantity-limit denials are often resolvable by demonstrating that the quantity requested matches the labeled dosing regimen.

For the exact approved dosing regimen (number of tablets per day, dosing interval, and standard supply quantity), consult the current FDA-approved prescribing information for acoramidis. Do not rely on any secondary source, including this page, for dosing specifics.

## Why This Denial Is Appealable

Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review of a quantity-limit denial. If the quantity prescribed matches the FDA-approved dosing regimen and is appropriate for the patient's treatment plan, that is a direct basis to request an exception. External review is available within approximately four months of a final internal denial, with an expedited option for urgent cases.

## Your Appeal Timeline

• Internal appeal: File within 180 days of the denial notice (confirm the exact date on your Explanation of Benefits).
• External review: Within approximately four months of the final internal denial.
• Expedited review: Request if the patient's condition is urgent and delay would cause harm.

## Documentation to Gather

1. FDA-approved prescribing label: Attach or reference the current FDA label for acoramidis, which documents the approved dosing regimen. This establishes that the quantity requested is consistent with labeled use. 2. Prescription and quantity requested: The exact prescription showing the dosing as ordered, so the reviewer can compare it to the label and to Aetna's limit. 3. Prescriber statement confirming dosing rationale: A brief letter from the prescribing cardiologist confirming that the quantity ordered reflects the FDA-approved regimen and the patient's ongoing treatment plan. 4. Confirmed ATTR-CM diagnosis: Background chart documentation confirming the diagnosis and the ongoing need for therapy. 5. Treatment continuity documentation: For patients already on therapy, documentation of adherence and clinical response supports the argument that a supply interruption would be clinically harmful.

## Criteria-Mapping Structure

Obtain Aetna's quantity-limit criteria for acoramidis from the relevant Clinical Policy Bulletin or pharmacy benefit documentation.

| Quantity-Limit Criterion | Supporting Evidence | |---|---| | Quantity matches FDA-labeled regimen | [FDA label dosing section] | | Ongoing medical necessity for therapy | [Chart note, diagnosis confirmation] | | Prescriber authorization for quantity | [Prescriber letter or PA documentation] | | No clinical reason to restrict below labeled amount | [Prescriber clinical statement] |

Quantity-limit appeals that demonstrate the requested amount is simply the standard labeled dose — not an excess — have a strong factual basis and are frequently approved on internal review.